Open access
Open access
Powered by Google Translator Translator

Editor's Choice

ACR/EULAR remission criteria for rheumatoid arthritis: 2022 Revision.

26 Oct, 2022 | 14:39h | UTC

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision – Arthritis & Rheumatology

Commentary: New ACR/EULAR Guideline Expands RA Remission Definition – MedPage Today (free registration required)

 

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

26 Oct, 2022 | 14:38h | UTC

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update – Annals of the Rheumatic Diseases

 

Review | Hypercalcemia.

26 Oct, 2022 | 14:37h | UTC

Hypercalcemia: A Review – JAMA (free for a limited period)

Author Interview: Hypercalcemia—A Review – JAMA

 

RCT | In critically ill patients receiving MV, there was no difference in outcomes between different O2 saturation targets.

25 Oct, 2022 | 13:23h | UTC

Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Study finds that the most common oxygen saturation targets for hospitalized patients appear equally safe and effective – Vanderbilt University Medical Center

Related:

Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial – JAMA

Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure – New England Journal of Medicine

Oxygen targets – Intensive Care Medicine (if the link is paywalled, try this one)

Thoracic Society of Australia and New Zealand Position Statement on Acute Oxygen Use in Adults: ‘Swimming between the flags’ – Respirology

Long-term mortality and health-related quality of life of lower versus higher oxygenation targets in ICU patients with severe hypoxaemia – Intensive Care Medicine

Oxygen Targets During Mechanical Ventilation in the ICU: A Systematic Review and Meta-Analysis – Critical Care Explorations

Higher versus lower oxygenation strategies in the general intensive care unit population: A systematic review, meta-analysis and meta-regression of randomized controlled trials – Journal of Critical Care

 

Commentary on Twitter

 

Diaphragmatic function in cardiovascular disease: JACC review topic of the week.

25 Oct, 2022 | 13:22h | UTC

Diaphragmatic Function in Cardiovascular Disease: JACC Review Topic of the Week – Journal of the American College of Cardiology

 

ASMBS Guidelines | Indications for metabolic and bariatric surgery.

24 Oct, 2022 | 14:17h | UTC

2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery – Surgery for Obesity and Related Diseases

News Release: After 30 years — new guidelines for weight-loss surgery – American Society for Metabolic and Bariatric Surgery

Commentary: New guidelines expand eligibility for weight loss surgery. Will insurance coverage follow? – USA Today

 

Commentary on Twitter

 

KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease.

24 Oct, 2022 | 14:16h | UTC

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease – Kidney International

See also: Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence – Kidney International

Related: ADA/KDIGO Consensus Report | Diabetes management in chronic kidney disease.

 

RCT | Ivermectin does not improve time to recovery in outpatients with mild to moderate COVID-19.

24 Oct, 2022 | 14:14h | UTC

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial – JAMA

Commentary: Ivermectin doesn’t speed time to recovery from nonsevere COVID – CIDRAP

 

Commentary on Twitter

 

Post-trial follow-up | Microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection.

24 Oct, 2022 | 14:15h | UTC

Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial – JAMA (free for a limited period)

Original Study: RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).

 

Commentary on Twitter

 

Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews.

24 Oct, 2022 | 14:13h | UTC

Conservative interventions for treating urinary incontinence in women: an Overview of Cochrane systematic reviews – Cochrane Library

Summary: Conservative interventions for urinary incontinence in women: an overview of Cochrane Reviews – Cochrane Library

 

ACC/AHA blood pressure categories – A systematic review of the relationship with adverse pregnancy outcomes.

21 Oct, 2022 | 13:05h | UTC

American College of Cardiology/American Heart Association blood pressure categories – a systematic review of the relationship with adverse pregnancy outcomes – American Journal of Obstetrics & Gynecology (PDF)

 

Commentary on Twitter

 

AGA clinical practice guideline on pharmacological interventions for adults with obesity.

21 Oct, 2022 | 13:06h | UTC

AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity – Gastroenterology

News Release: First medical guideline recommends new prescription medications for weight loss, ranks the most effective drugs – American Gastroenterological Association

 

Brief Review | Management of oliguria.

21 Oct, 2022 | 13:04h | UTC

Management of oliguria – Intensive Care Medicine (if the link is paywalled, try this one)

 

Commentary on Twitter

 

Two Phase 3, randomized, controlled trials of Ruxolitinib cream for vitiligo.

21 Oct, 2022 | 13:03h | UTC

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Ruxolitinib Cream Results in Greater Repigmentation in Vitiligo – HealthDay

 

RCT | Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age.

20 Oct, 2022 | 12:35h | UTC

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age – New England Journal of Medicine

 

Commentary on Twitter

 

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

20 Oct, 2022 | 12:34h | UTC

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine

 

Commentary on Twitter

 

Perspective | Could, should families watch their loved one’s surgeries and, if so, when?

20 Oct, 2022 | 12:33h | UTC

Could, Should Families Watch Their Loved One’s Surgeries and, If So, When? – Anesthesia & Analgesia (free for a limited period)

 

Crossover RCT | Spinal cord burst stimulation does not improve disability in chronic radicular pain after lumbar spine surgery.

19 Oct, 2022 | 14:29h | UTC

Effect of Spinal Cord Burst Stimulation vs Placebo Stimulation on Disability in Patients With Chronic Radicular Pain After Lumbar Spine Surgery: A Randomized Clinical Trial – JAMA (free for a limited period)

 

Commentary on Twitter

 

Pooled analysis of cohort studies | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters.

19 Oct, 2022 | 14:28h | UTC

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales – The Lancet

Commentaries:

Prioritisation of COVID-19 boosters in the omicron era – The Lancet

COVID booster halved severe illness, but some groups still at higher risk – CIDRAP

 

RCT | Efficacy of BCG vaccination in reducing the incidence and severity of COVID-19 in a high-risk population.

19 Oct, 2022 | 14:26h | UTC

Efficacy of Bacillus Calmette–Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial – Infectious Diseases and Therapy

 

Case-control study | Odds of hospitalization for COVID-19 after 3 vs. 2 doses of mRNA vaccine by time since booster dose.

19 Oct, 2022 | 14:27h | UTC

Odds of Hospitalization for COVID-19 After 3 vs 2 Doses of mRNA COVID-19 Vaccine by Time Since Booster Dose – JAMA

News Release: Study indicates COVID-19 boosters among vaccinated individuals significantly reduce hospitalization rates – Providence Health & Services

 

Retrospective Cohort Study | Trends in the association between diabetes and cardiovascular events, 1994-2019.

18 Oct, 2022 | 12:58h | UTC

Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 – JAMA (free for a limited period)

Related Study: Study shows that the leading causes of hospitalization of adults with diabetes are changing.

 

Cluster RCT | Primary prophylaxis with CSFs fails to improve outcomes in patients at intermediate risk for febrile neutropenia.

18 Oct, 2022 | 12:58h | UTC

A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia – Journal of Clinical Oncology

 

RCT | Moderate vs. intensive pushing during the active phase of the 2nd stage of labor among nulliparous women with an epidural.

18 Oct, 2022 | 12:56h | UTC

Alternative to intensive management of the active phase of the second stage of labor: a multicenter randomized trial (Phase Active du Second STade trial) among nulliparous women with an epidural – American Journal of Obstetrics & Gynecology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

RCT | Two-year effects of Semaglutide in adults with overweight or obesity.

18 Oct, 2022 | 12:53h | UTC

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial – Nature Medicine

Commentary: STEP 5: Sustained semaglutide treatment maintains weight loss – medwire News

Related:

RCT: Effect of continued weekly subcutaneous Semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity

RCT: High dose once a week Semaglutide (2.4 mg) in adults with overweight or obesity, and type 2 diabetes

RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity

RCT: Once-weekly, high-dose semaglutide is effective for improving overweight or obesity among non-diabetic adults

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.